Constitutive Activity of the Serotonin2C Receptor InhibitsIn VivoDopamine Release in the Rat Striatum and Nucleus Accumbens
Open Access
- 31 March 2004
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 24 (13) , 3235-3241
- https://doi.org/10.1523/jneurosci.0112-04.2004
Abstract
Numerous research has pointed out that serotonin2c (5-HT2C) receptor, a subtype of 5-HT receptors belonging to the G-protein-coupled receptor superfamily, modulates the activity of mesencephalic dopamine (DA) neurons, the dysfunction of which is involved in devastating diseases such as schizophrenia, Parkinson's disease, and drug addiction. In the present study, using in vivo intracerebral microdialysis and Chinese hamster ovary (CHO) cells expressing 5-HT2C receptors to identify appropriate 5-HT2C receptor ligands, we sought to determine whether the property of 5-HT2C receptors to spontaneously activate intracellular signaling pathways in vitro (constitutive activity) participates in the tonic inhibitory control that they exert on DA release in the rat striatum and nucleus accumbens in vivo. In CHO cells, the purported antagonist 5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f] indole hydrochloride (SB 206553), but not 6-chloro-5-methyl-1-[6-(2-methylpiridin-3-yloxy)pyridin-3-yl carbamoyl] indoline (SB 242084), decreased basal inositol phosphate accumulation, thus behaving as a 5-HT2C inverse agonist. Its effect was prevented by SB 242084. In vivo, SB 206553 (1–10 mg/kg) elicited a dose-dependent and clear-cut increase in accumbal and striatal DA release compared with SB 242084 (1–10 mg/kg), and the 5-HT2C agonist S-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine hydrochloride (Ro-60-0175) (0.3–3 mg/kg) inhibited DA release. Pretreatment by SB 242084 reversed the change in DA release elicited by Ro-60-0175 and SB 206553. Furthermore, SB 206553-stimulated DA release was insensitive to reduction of 5-HT neuronal function induced by the 5-HT1A agonist (±)-8-hydroxy-2-dipropylaminotetralin or intra-raphe injections of 5,7-dihydroxytryptamine neurotoxin. The obtained results provide the first in vivo evidence that constitutive activity of the 5-HT2C receptor tonically inhibits mesencephalic DA neurons and underscore the need for a better understanding of the pathophysiological role of constitutive receptor activity.Keywords
This publication has 37 references indexed in Scilit:
- Constitutive activity of receptors coupled to guanine nucleotide regulatory proteinsPublished by Elsevier ,2002
- 5-HT2A and 5-HT2C/2B Receptor Subtypes Modulate Dopamine Release Induced in Vivo by Amphetamine and Morphine in Both the Rat Nucleus Accumbens and StriatumNeuropsychopharmacology, 2002
- RNA Editing of the Human Serotonin 5-HT2CReceptor Alters Receptor-mediated Activation of G13ProteinJournal of Biological Chemistry, 2001
- 5‐HT2C receptor antagonists: Potential in schizophreniaDrug Development Research, 2001
- Inverse, protean, and ligand‐selective agonism: matters of receptor conformationThe FASEB Journal, 2001
- The Role of Serotonin in Antipsychotic Drug ActionNeuropsychopharmacology, 1999
- Regulation of serotonin-2C receptor G-protein coupling by RNA editingNature, 1997
- Agonist-receptor efficacy II: agonist trafficking of receptor signalsTrends in Pharmacological Sciences, 1995
- Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptorsNature, 1995
- THE FUNCTIONAL ROLE OF MESOTELENCEPHALIC DOPAMINE SYSTEMSBiological Reviews, 1992